CEO succession clarity and a record deal calendar make GS compelling as rising long-term rates knock the...
With 54% of Zenkuda patients at six-month dosing and a Q4 BLA plan, the stock surge may...
Warren’s probe raises a question investors have dodged: how much of the AI capex boom rests on...
August’s 4.2% profit growth, the weakest of 2026, shows what Sept. 30’s PMI may confirm and what...
August industrial profits rose 4.2%, the slowest pace of the year, with official surveys due Wednesday and...
The FDA approved Onswik on September 23. The harder question is whether Lilly can manufacture it fast...
The biotech IPO class of 2026 has held up better than expected. ADARx’s first-week fade puts that...
The difference between an earnings-trick buyback and a real valuation call is when management pulls the trigger.
When Tokyo, Paris, and Washington sell off together, this is global, not just Treasuries.
With Q3 closing Wednesday and tax-loss selling hitting consumer names, the real question is which one has...